ClinicalTrials.gg
CompletedNCT01890629STABLEUpdated Mar 13, 2015

Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)

A Phase 4 interventional study of Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin in Type 2 Diabetes Mellitus, sponsored by LG Life Sciences. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-03-13.

Sponsored by LG Life Sciences (part of LG Chem) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. gemigliptin · Diabetes Mellitus, Type 2.

Enrollment
11th of 18
69 · median 130
Started
2013
with 1 other
Phase 4
3 of 18
none open now
Registered
4th of 18
by date
Lead sponsor
8 of 18
LG Life Sciences

Among the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 2 that started in 2013, is one of 3 in phase 4, and was the 4th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About gemigliptin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

To compare efficacy and safety of initial combination therapy of Gemigliptin versus Sitagliptin or Glimepiride with Metformin on Glucose Variability(MAGE, Glucose SD) in Patients With Type 2 Diabetes Mellitus.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • diabetes mellitus
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Type 2 Diabetes Mellitus
  • adults aged ≥ 20 and aged ≤ 70 years old
  • Patients who had not taken anti diabetes drug for 8 weeks prior to screening visit with ≥ 7.5%
  • All patients give written
  • Patients applicable to any one of following 3 categories

    1. Patients with surgically induced infertility
    2. woman ≥45 years of age with over 2 years from the last menstruation
    3. Fertile pre-menopause woman or male patients who has consented for use of two or more methods at least up to 14 days after final administration of the product to avoid getting pregnant

Exclusion criteria

Exclusion Criteria:

  • Patients with Type 1 Diabetes, Patients with Diabetic Ketoacidosis or Diabetic Coma as well as Pre-coma
  • Patients with Gestational Diabetes Mellitus or with Secondary Diabetes
  • Patients with Class III, IV Congestive Heart Failure or with Treatment-requiring Arrhythmia
  • Patients with Thyroid Dysfunction whose TSH is out of normal range, requiring medication therapy
  • Patients with pituitary insufficiency or hypoadrenalism
  • Patients whose is less than 20 Kg/m2 or exceeds 40 Kg/m2
  • Patients whose Total level is 1.5 times higher than the and /AST are > 2.5 times higher than the upper limit of normal range
  • Patients currently taking strong inducers
  • Patients currently taking Warfarin, Dicoumar or Digoxin
  • Patients currently taking any medication from within 4 weeks before Visit 1 (screening) likely to have significant effects on glycemic control or who require to take such medication
  • Patients who had taken anti-obesity drugs within 12 weeks in prior to Visit 1 (screening)
  • Subject who had been treated with Insulin or GLP-1 analogue within 6 months before Visit 1 (screening)
  • Patients who had participated in other clinical study in the past 3 months before Visit 1 (screening)
  • Any other patients whom the investigator considers as inadequate for this study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Gemigliptin + Metformin

    Gemigliptin 50 mg + Metformin 500 mg to 1000mg for 12 weeks

    Drug: Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin

  • Active comparator
    Sitagliptin + Metformin

    Sitagliptin 100 mg + Metformin 500 mg to 1000mg for 12 weeks

    Drug: Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin

  • Active comparator
    Glimepiride + Metformin

    Glimepiride 2 mg + Metformin 500 mg to 1000mg for 12 weeks

    Drug: Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Amplitude Glycemic Excursion

    Time frame: Change of MAGE at Week 12 from baseline

Secondary outcomes

  1. Glucagon

    Time frame: Change of Glucagon at Week 12 from baseline

  2. Active GLP-1

    Time frame: Change of Active GLP-1 at Week 12 from baseline

  3. CRP

    Time frame: Change of CRP at Week 12 from baseline

  4. Nitrotyrosine

    Time frame: Change of nitrotyrosine at Week 12 from baseline

  5. Glycated albumin

    Time frame: Change of glycated albumin at Week 4 from baseline

  6. Fructosamine

    Time frame: Change of fructosamine at Week 4 from baseline

  7. Glucose Standard Deviation in CGMS data

    Time frame: Change of Glucose SD at Week 12 from baseline

07

Study locations

1 site
  • Severance hospital
    Seoul, 120-752, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2013
First posted
Jul 2, 2013
Start
May 2013
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Last update
Mar 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01890629
Lead sponsor
LG Life Sciences
Responsible party
Sponsor
First posted
Jul 2, 2013
Start date
May 2013
Primary completion
Aug 2014
Completion
Aug 2014
Last update
Mar 13, 2015

Study contacts

SE Park
principal investigator · Kangbuk Samsung Hospital
BW Lee
principal investigator · Severance Hospital
JH Jo
principal investigator · Seoul St. Mary's Hospital
JH Kim
principal investigator · Samsung Medical Center
JH Jung
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemigliptin · Metformin · Sitagliptin · Glimepiride

Start the discussion